BriaCell Other Current Liab from 2010 to 2025

BCTXW Stock  USD 0.11  0.01  10.00%   
BriaCell Therapeutics Other Current Liabilities yearly trend continues to be fairly stable with very little volatility. Other Current Liabilities is likely to outpace its year average in 2025. During the period from 2010 to 2025, BriaCell Therapeutics Other Current Liabilities regression line of quarterly data had mean square error of 777.1 B and geometric mean of  331,726. View All Fundamentals
 
Other Current Liabilities  
First Reported
2008-07-31
Previous Quarter
754.7 K
Current Value
227.6 K
Quarterly Volatility
875.4 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check BriaCell Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BriaCell Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 18.4 K, Interest Expense of 0.0 or Other Operating Expenses of 40.2 M, as well as many indicators such as Price To Sales Ratio of 0.0, Days Sales Outstanding of 0.0 or Invested Capital of 622.1 K. BriaCell financial statements analysis is a perfect complement when working with BriaCell Therapeutics Valuation or Volatility modules.
  
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

Latest BriaCell Therapeutics' Other Current Liab Growth Pattern

Below is the plot of the Other Current Liab of BriaCell Therapeutics Corp over the last few years. It is BriaCell Therapeutics' Other Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BriaCell Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Other Current Liab10 Years Trend
Pretty Stable
   Other Current Liab   
       Timeline  

BriaCell Other Current Liab Regression Statistics

Arithmetic Mean622,672
Geometric Mean331,726
Coefficient Of Variation137.82
Mean Deviation527,247
Median342,679
Standard Deviation858,139
Sample Variance736.4B
Range3.4M
R-Value0.12
Mean Square Error777.1B
R-Squared0.02
Significance0.65
Slope22,179
Total Sum of Squares11T

BriaCell Other Current Liab History

2025657.3 K
2024333.9 K
2023290.4 K
2022677.7 K
2021477.8 K
2020342.7 K
20193.4 M

About BriaCell Therapeutics Financial Statements

BriaCell Therapeutics investors use historical fundamental indicators, such as BriaCell Therapeutics' Other Current Liab, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in BriaCell Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Other Current Liabilities333.9 K657.3 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for BriaCell Stock Analysis

When running BriaCell Therapeutics' price analysis, check to measure BriaCell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BriaCell Therapeutics is operating at the current time. Most of BriaCell Therapeutics' value examination focuses on studying past and present price action to predict the probability of BriaCell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BriaCell Therapeutics' price. Additionally, you may evaluate how the addition of BriaCell Therapeutics to your portfolios can decrease your overall portfolio volatility.